- Amylyx Pharmaceuticals ( NASDAQ: AMLX ) said that initial sales of its amyotrophic lateral sclerosis treatment, Relyvrio, approved in late September 2022, are much better than expected and will exceed consensus.
- Relyvrio (taurursodiol and sodium phenylbutyrate) comes with a steep annual list price of $156K.
- Amylyx ( AMLX ) will provide an update on the commercial launch of the therapy on Tuesday at the SVB Securities Global Biopharma Conference. Further information on Q4 2022 and full-year sales will come on its March 30 earnings call.
- The company also said it expects the European Medicines Agency to act on its application for Relyvrio in the first half of the year.
- Amylyx ( AMLX ) noted that insurers representing about 25% of covered lives have issued determinations with nearly all providing broad access. The majority of payers are expected to render determinations in 1H 2023 .
- Cigna ( CI ) recently decided it will not cover Relyvrio saying it lacks clinical efficacy data and unclear clinical benefit.
- Read why Seeking Alpha contributor Avisol Capital Partners considers Amylyx ( AMLX ) a hold.
For further details see:
Amylyx says sales of new ALS therapy Relyvrio better than projected, above consensus